Curetis AG focuses on multiparameter testing of many analytes in a single run, providing broad panels of combined pathogen and resistance gene detection for a wide range of diseases.

Curetis integrates today´s molecular diagnostics laboratory into one instrument for the detection of severe bacterial infections as a first target application. However, the universal platform will also allow the future expansion into other clinical applications with additional market opportunities beyond infectious diseases.

Patents 91show all

  • 54
    C12Q - Measuring or testing processes involving enzymes, nucleic acids or microorganisms
  • 22
    G16B - Bioinformatics, i.e. information and communication technology [ict] specially adapted for genetic or protein-related data processing in computational molecular biology
  • 20
    C12N - Microorganisms or enzymes
  • 17
    B01L - Chemical or physical laboratory apparatus for general use
  • 15
    G01N - Investigating or analysing materials by determining their chemical or physical properties
  • 9
    G16H - Healthcare informatics, i.e. information and communication technology [ict] specially adapted for the handling or processing of medical or healthcare data
  • 7
    C12M - Apparatus for enzymology or microbiology
  • 6
    Y02A - Technologies for adaptation to climate change
  • 5
    B01D - Separation
  • 5
    C12P - Fermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture

Clinical Trials 2show all

1N/A

Contact Information

Max-Eyth-Straße 42
Holzgerlingen D-71088
Germany

Overview

Total FundingEmployeesLast Funding DateStatus
$90,762,33511-502018-10-02Ipo

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2018-10-02$23,101,090Post Ipo Debt
2010-05-31$1,847,465Series A
2011-05-17$6,387,817Series A
2009-12-03$27,910,330Series AKfW, BioMedPartners, Aeris Capital, Life Sciences Partners
2014-11-20$18,187,724Series BLife Sciences PartnersRoche Venture Fund, HBM Partners, BioMedPartners, CD-Venture, Forbion Capital Partners, Aeris Capital
2011-10-26$13,327,909Series AForbion Capital PartnersRoche Venture Fund